Newer amylin analogs such as davalintide, PEGylated amylin and dual amylin/calcitonin agonists are in pre-clinical development for diabetes/obesity treatment, as yet there are no published clinical trials (47). This evidence concerns the gene IAPP and obesity due to melanocortin 4 receptor deficiency.